Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments

Related Content

Sanofi's Lixisenatide Shows Challenges Of Being Late Entrant In Class

May 30 2016

Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say

Jul 04 2016

Diabetes Combos: Novo, Sanofi May Need New Treatment Paradigm To Match Products

May 30 2016

Related Companies

Sanofi

Eli Lilly and Company

Novo Nordisk A/S

Additional Topics

United States Approvals Drug Review Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window